YAP1 and colorectal carcinoma: USP52 interacts with YAP and inhibits YAP polyubiquitination and breakdown, which further decreases the sensitivity of CRC cells to ferroptosis and ultimately attenuates immunotherapy efficacy (Fig. 8).